RU2012147102A - METHOD FOR PREDICTING THE COURSE OF ISCHEMIC HEART DISEASE - Google Patents
METHOD FOR PREDICTING THE COURSE OF ISCHEMIC HEART DISEASE Download PDFInfo
- Publication number
- RU2012147102A RU2012147102A RU2012147102/15A RU2012147102A RU2012147102A RU 2012147102 A RU2012147102 A RU 2012147102A RU 2012147102/15 A RU2012147102/15 A RU 2012147102/15A RU 2012147102 A RU2012147102 A RU 2012147102A RU 2012147102 A RU2012147102 A RU 2012147102A
- Authority
- RU
- Russia
- Prior art keywords
- apo
- less
- blood serum
- total cholesterol
- course
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- 208000031225 myocardial ischemia Diseases 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract 12
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract 6
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract 6
- 235000012000 cholesterol Nutrition 0.000 claims abstract 6
- 210000002966 serum Anatomy 0.000 claims abstract 6
- 238000001962 electrophoresis Methods 0.000 claims abstract 4
- 238000011534 incubation Methods 0.000 claims abstract 4
- 238000004393 prognosis Methods 0.000 claims abstract 4
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract 2
- 229920004890 Triton X-100 Polymers 0.000 claims abstract 2
- 239000013504 Triton X-100 Substances 0.000 claims abstract 2
- 239000011543 agarose gel Substances 0.000 claims abstract 2
- 208000029078 coronary artery disease Diseases 0.000 claims abstract 2
- 238000000326 densiometry Methods 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 238000001035 drying Methods 0.000 claims abstract 2
- 230000002349 favourable effect Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims abstract 2
- 230000007704 transition Effects 0.000 claims abstract 2
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Способ прогнозирования течения ишемической болезни сердца путем исследования сыворотки крови, отличающийся тем, что до и после лечения одновременно определяют в сыворотке крови Апо А-1, общий холестерин и ЛП(а), путем дополнительной обработки 0,5 мл 0,1 мл 0,1%-ного раствора Тритона Х-100 и инкубации 15 мин при 20°С, перемешивании смеси методом встряхивания 120 раз в 1 мин, последующей инкубации сыворотки крови больного с раствором Судана Б в течение 1 ч в темном термостате при 40°С и затем внесении пробы в лунку в геле агарозы с площадью основания 4×20 мм для электрофореза и последующей фиксации электрофореграмм, их высушивании, денситометрии и при одновременном снижении уровня общего холестерина на 18% и более и ЛП(а) на 30% и более и увеличении Апо А-1 на 25% и более по сравнению с исходным уровнем; прогноз течения заболевания считают благоприятным, способствующим переходу стенокардии напряжения из функционального класса III-IV в функциональный класс I-II, а при снижении общего холестерина менее 18%, уровня ЛП(а) менее 30% и увеличением Апо А-1 менее 25% по сравнению с исходным прогноз считают неблагоприятным.A method for predicting the course of coronary heart disease by examining blood serum, characterized in that before and after treatment, Apo A-1, total cholesterol and PL (a) are simultaneously determined in blood serum by additional treatment with 0.5 ml 0.1 ml 0, 1% solution of Triton X-100 and incubation for 15 min at 20 ° C, stirring the mixture by shaking 120 times in 1 min, followed by incubation of the patient’s blood serum with Sudan B solution for 1 h in a dark thermostat at 40 ° C and then making a sample in a well in agarose gel with a base area of 4 × 20 mm for electrophoresis and subsequent fixation of electrophoregrams, their drying, densitometry, while reducing total cholesterol by 18% or more and PL (a) by 30% or more and increasing Apo A-1 by 25% or more compared to the initial level; the prognosis of the course of the disease is considered favorable, contributing to the transition of exertional angina from functional class III-IV to functional class I-II, and with a decrease in total cholesterol of less than 18%, an LP level (a) of less than 30% and an increase in Apo A-1 of less than 25% Compared with the initial prognosis is considered unfavorable.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012147102/15A RU2520755C1 (en) | 2012-11-06 | 2012-11-06 | Method for prediction of clinical course of ischemic heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012147102/15A RU2520755C1 (en) | 2012-11-06 | 2012-11-06 | Method for prediction of clinical course of ischemic heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012147102A true RU2012147102A (en) | 2014-05-20 |
| RU2520755C1 RU2520755C1 (en) | 2014-06-27 |
Family
ID=50695328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012147102/15A RU2520755C1 (en) | 2012-11-06 | 2012-11-06 | Method for prediction of clinical course of ischemic heart disease |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2520755C1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2210076C2 (en) * | 2000-09-01 | 2003-08-10 | Сибирский государственный медицинский университет | Method for predicting the flow of ischemic cardiac disease |
| RU2402016C1 (en) * | 2009-02-02 | 2010-10-20 | Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Method of predicting course of coronary heart disease |
| RU2439576C1 (en) * | 2010-06-11 | 2012-01-10 | Государственное образовательное учреждение высшего профессионального образования "Национальный исследовательский Томский политехнический университет" | Method of predicting ischemic heart disease course |
| RU2428698C1 (en) * | 2010-06-11 | 2011-09-10 | Государственное образовательное учреждение высшего профессионального образования "Национальный исследовательский Томский политехнический университет" | Method of fraction test of modified blood lipoproteins |
-
2012
- 2012-11-06 RU RU2012147102/15A patent/RU2520755C1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2520755C1 (en) | 2014-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paneni et al. | The aging cardiovascular system: understanding it at the cellular and clinical levels | |
| Ma et al. | Elevated serum IL-6 and adiponectin levels are associated with frailty and physical function in Chinese older adults | |
| Emanuele et al. | Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity | |
| Muzzarelli et al. | Predictors of early readmission or death in elderly patients with heart failure | |
| Aydin et al. | Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology | |
| Colombo et al. | Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect? | |
| Wang et al. | Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes | |
| Goldraich et al. | Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression | |
| Lee et al. | Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan—a 3-year prospective study | |
| EA201500373A1 (en) | MASITINIB OR ITS SALT FOR THE TREATMENT OF CANCER, PHARMACEUTICAL COMPOSITION, MEDICINE AND SET | |
| Tschakert et al. | Acute physiological responses to short-and long-stage high-intensity interval exercise in cardiac rehabilitation: a pilot study | |
| Peng et al. | High glucose induces activation of the local renin-angiotensin system in glomerular endothelial cells | |
| Zhang et al. | Angiotensin II silencing alleviates erectile dysfunction through down-regulating the Rhoa/Rho kinase signaling pathway in rats with diabetes mellitus | |
| Skrzypczyk et al. | Renalase in children with chronic kidney disease | |
| Wei et al. | Noise exposure and its relationship with postinfarction cardiac remodeling: implications for NLRP3 inflammasome activation | |
| RU2012147102A (en) | METHOD FOR PREDICTING THE COURSE OF ISCHEMIC HEART DISEASE | |
| RU2009103367A (en) | METHOD FOR ESTIMATING EFFECTIVENESS OF TREATMENT OF ISCHEMIC HEART DISEASE | |
| RU2009103462A (en) | METHOD FOR FORECASTING THE COURSE OF ISCHEMIC HEART DISEASE | |
| Carbajales et al. | Prevalence of cardiac arrhythmias and distal conduction disorders in patients with chronic Chagas’ disease and elevated autoantibodies against M2 muscarinic acetylcholine receptors | |
| RU2011132235A (en) | METHOD FOR FORECASTING THE COURSE OF ISCHEMIC HEART DISEASE | |
| RU2009145864A (en) | METHOD FOR Predicting Heart Dysadaptation in Children After Cardiac Surgery Correction of Congenital Heart Disease | |
| RU2011131413A (en) | METHOD FOR ESTIMATING EFFECTIVENESS OF TREATMENT OF ISCHEMIC HEART DISEASE | |
| Ettala et al. | Erectile dysfunction cannot be used in primary screening of pre-diabetes | |
| León | Effect of moderate exercise on skeletal muscle mitochondrial function and dynamics in obese Zucker rats | |
| RU2425378C1 (en) | Method for prediction of atypical antipsychotic drug treatment rates in shizophrenics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141107 |